Biomarkers for severe eosinophilic asthma.

Biomarkers for severe eosinophilic asthma.

The last decade has seen the approval of several new biologics for the treatment of severe asthma-targeting specific endotypes and phenotypes. This review will examine how evidence generated from the mepolizumab clinical development program showed that blood eosinophil counts, rather than sputum or...

書誌詳細
主要な著者:	Yancey, S, Keene, O, Albers, F, Ortega, H, Bates, S, Bleecker, E, Pavord, I
フォーマット:	Journal article
言語:	English
出版事項:	Elsevier 2017

類似資料

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
著者:: Yancey, S, 等
出版事項: (2016)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
著者:: Ortega, H, 等
出版事項: (2016)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
著者:: Gunsoy, N, 等
出版事項: (2017)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
著者:: Shrimanker, R, 等
出版事項: (2018)

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
著者:: Pavord, I, 等
出版事項: (2012)

Mepolizumab treatment in patients with severe eosinophilic asthma.
著者:: Ortega, H, 等
出版事項: (2014)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
著者:: Bel, E, 等
出版事項: (2014)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
著者:: Steven W. Yancey, 等
出版事項: (2019-09-01)

Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide and their combination in severe asthma: a post-hoc analysis
著者:: Shrimanker, R, 等
出版事項: (2019)

Glucocorticoids and mepolizumab in eosinophilic asthma.
著者:: Bel, E, 等
出版事項: (2014)

Mepolizumab, quality of life, and severe eosinophilic asthma.
著者:: Pavord, I
出版事項: (2017)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
著者:: Howell, I, 等
出版事項: (2024)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
著者:: Prazma CM, 等
出版事項: (2021-06-01)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
著者:: Imran Howell, 等
出版事項: (2024-07-01)

Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
著者:: Terufumi Shimoda, 等
出版事項: (2017-07-01)

Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis
著者:: Charlene M. Prazma, 等
出版事項: (2019-05-01)

Eosinophils in asthma and airway hyperresponsiveness.
著者:: Brightling, C, 等
出版事項: (2004)

Feno and blood eosinophils as biomarkers in predicting asthma exacerbations
著者:: Rastogi, S, 等
出版事項: (2017)

Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma.
著者:: Kulkarni, N, 等
出版事項: (2010)

Non-eosinophilic asthma and the innate immune response.
著者:: Pavord, I
出版事項: (2007)

Severe eosinophilic asthma: a roadmap to consensus.
著者:: Buhl, R, 等
出版事項: (2017)

Mepolizumab in refractory eosinophilic asthma.
著者:: Pavord, I, 等
出版事項: (2010)

IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma
著者:: Luo, J, 等
出版事項: (2024)

A retrospective cohort study in severe asthma describing commonly measured biomarkers: Eosinophil count and IgE levels
著者:: Haughney, J, 等
出版事項: (2017)

Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies
著者:: Mi-Kyeong Kim, 等
出版事項: (2021-03-01)

Eosinophilic bioactivities in severe asthma
著者:: Tara F. Carr, 等
出版事項: (2016-01-01)

Non-eosinophilic corticosteroid unresponsive asthma.
著者:: Pavord, I, 等
出版事項: (1999)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
著者:: Shrimanker, R, 等
出版事項: (2017)

Controversies in allergy: should severe asthma with eosinophilic phenotype always be treated with anti-IL-5 therapies
著者:: Pavord, I, 等
出版事項: (2019)

Eosinophils in asthma and other allergic diseases.
著者:: Wardlaw, A, 等
出版事項: (2000)

The significance of eosinophilic airway inflammation in asthma
著者:: Pavord, I, 等
出版事項: (2002)

Comparison of airway immunopathology of eosinophilic bronchitis and asthma.
著者:: Brightling, C, 等
出版事項: (2003)

Asthma heterogeneity and severity
著者:: Tara F. Carr, 等
出版事項: (2016-01-01)

Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
著者:: Pavord, I, 等
出版事項: (2017)

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA
著者:: Frank C. Albers, 等
出版事項: (2019-07-01)

Eosinophils in COPD: just another biomarker?
著者:: Bafadhel, M, 等
出版事項: (2017)

Occupational asthma due to low molecular weight agents: eosinophilic and non-eosinophilic variants.
著者:: Anees, W, 等
出版事項: (2002)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
著者:: Moran, AM, 等
出版事項: (2020)

Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment
著者:: Lavoie, G, 等
出版事項: (2024)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
著者:: Shrimanker, R, 等
出版事項: (2017)